Studies not specific to one type of cancer

Trial A Phase I trial of LY3143921 hydrate in solid tumours
Cancer Type Non-specific
Hospital(s) Belfast City Hospital
Information

A Cancer Research UK phase I trial of LY3143921 hydrate (a CDC7 inhibitor) given orally once daily in adult patients with advanced solid tumours

Trial Add-Aspirin Trial
Cancer Type Bowel Cancer, Breast Cancer, Oesophageal Cancer, Prostate Cancer, Stomach Cancer, and Non-specific
Hospital(s) Antrim Hospital, Belfast City Hospital, and Craigavon Hospital
Information

A Phase III, Double-Blind, Placebo-Controlled Randomised Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival after Primary Therapy in Common Non-Metastatic Solid Tumours

Click Here to view CancerHelpUK trial summary
Trial CaPP3
Cancer Type Non-specific
Hospital(s) Belfast City Hospital
Information

A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg versus 100mg of enteric coated aspirin as a cancer preventive in carriers of a germline pathological mismatch repair gene defect, Lynch Syndrome. Project 3 in the Cancer Prevention Programme

Click Here to view CancerHelpUK trial summary
Trial CellCentric
Cancer Type Non-specific
Hospital(s) Belfast City Hospital
Information

An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid/metastatic tumours

Trial CellCentric CCS1477-01
Cancer Type Non-specific
Hospital(s) Belfast City Hospital
Information

An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid/metastatic tumours

Trial EASI-SWITCH
Cancer Type Non-specific
Hospital(s) Altnagelvin Hospital, Belfast City Hospital, and Ulster Hospital
Information

Early Switch to Oral Antibiotic Therapy in Patients with Low Risk Neutropenic Sepsis

Trial FAK-PD1
Cancer Type Non-specific
Hospital(s) Belfast City Hospital
Information

A Phase I/IIA Study to Assess Safety, Tolerability and Preliminary Activity of FAK (defactinib) and PD-1 (Pembrolizumab) Inhibition in Patients with Advanced Solid Malignancies

Click Here to view CancerHelpUK trial summary
Trial NuTide:301
Cancer Type Non-specific
Hospital(s) Belfast City Hospital
Information

A TWO-PART, PHASE I OPEN LABEL, DOSE ESCALATION AND EXPANSION STUDY TO ASSESS SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF NUC-3373, A NUCLEOTIDE ANALOGUE, IN PARTICIPANTS WITH ADVANCED SOLID TUMOURS

Click Here to view CancerHelpUK trial summary
Trial NuTide:301
Cancer Type Non-specific
Hospital(s) Belfast City Hospital
Information

A two-part, phase 1 open label, dose escalation and expansion study to assess safety, pharmacokinetics and clinical activity of nuc-3373, a nucleotide analogue, in participants with advanced solid tumours